HIV Infections
Conditions
Keywords
Langerhans Cells, Dinitrochlorobenzene, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Brief summary
To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.
Interventions
Sponsors
University of California, San Francisco
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
Patients must have the following: * Stage III or IV HIV infection. * Provide informed consent.
Exclusion criteria
Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Kaposi's sarcoma lesions in the proposed treatment sites. * Liable to require radiation or chemotherapy during the course of the study. * Not likely to survive the length of the study. * Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.: * holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine. Concurrent Medication: Excluded: * Other Immunomodulators. Concurrent Treatment: Excluded: * Radiation. Patients with the following are excluded: * Kaposi's sarcoma lesions in the proposed treatment sites. * Liable to require radiation or chemotherapy during the course of the study. * Not likely to survive the length of the study. * Obvious ultra-violet-irradiated skin damage in the treatment areas. * Allergy to lidocaine. Prior Medication: Excluded: * Prior DNCB therapy.
Countries
United States
Outcome results
None listed